

DRUG ABUSE WARNING NETWORK DETAILED EMERGENCY DEPARTMENT (ED) TABLES 1998

**Office of Applied Studies
Substance Abuse and Mental Health Services Administration
Department of Health and Human Services**

TABLE OF CONTENTS

Section

LIST OF TABLES

THINGS TO REMEMBER

SYMBOLS USED IN TABLES

ACKNOWLEDGMENTS

PUBLIC DOMAIN NOTICE

1 INTRODUCTION

Background and Methodology

Statistical Sample of Emergency Departments

Data Limitations

Table Reporting Format

2 RATES OF DAWN ED DRUG ABUSE EPISODES AND DRUG MENTIONS RELATIVE TO TOTAL POPULATION

3 ESTIMATION PROCEDURE AND PRECISION OF ESTIMATES

Estimation Procedure

Precision of Estimates and Standards for Publication

Correction of the Estimation System for 1995

4 DAWN EMERGENCY DEPARTMENT REPORT FORM

5 GLOSSARY OF TERMS

LIST OF TABLES

Relative Standard Error (RSE) Tables were added beginning with the Internet publication of the *1998 Detailed ED Tables* from DAWN. The RSEs in these tables can assist users in interpreting information in the detailed data tables. RSE table numbers have the prefix "RSE-", and for ease of use, the RSE table numbers match their counterpart data tables. A description of RSEs and their uses can be found in Section 3 under [Precision of Estimates and Standards for Publication](#).

Beginning with the *1998 Detailed ED Tables*, a few tables have been assigned new numbers. In addition, shortened table titles are listed in this Table of Contents to help readers quickly locate data of interest. A listing of [Tables in Numeric Order with References to Table Numbers in DAWN Annual Reports Prior to 1998](#), which lists the full table titles, is provided to help users easily match these tables to similar tables in previous DAWN "Annual" ED reports.

Data Table

RSE Table

SAMPLING & PRECISION

This group of tables provides information by metropolitan area on the sample and measures of precision associated with these data.

Information on the Sample

- 1.01 DAWN sample and response rates
- 1.02 Total ED visits, episodes, & mentions (weighted & unweighted)
- 1.03 Counties & cities comprising 21 metropolitan areas

Measures of Precision

Tables 1.04, 1.05, and 1.06 provide examples of estimates, RSEs, and other measures of precision. These tables were previously located in Appendix II where they were numbered II-1, II-2, and II-3, respectively.

- 1.04 Total episodes by metropolitan area
- 1.05 Total episodes & mentions for selected drugs for coterminous U.S.
- 1.06 Total episodes & mentions for common illicit drugs by metropolitan area

Data Table**RSE Table****MOST FREQUENTLY MENTIONED DRUGS****Individual Drugs**

- [2.06a](#) In descending frequency order
- [2.06b](#) In alphabetical order
- [2.06c](#) Top 15 drugs by age
- [2.06d](#) Top 15 drugs by race/ethnicity
- [2.06e](#) Top 15 drugs by gender

Drug Combinations

- [2.19](#) Number of other drugs by drug group [RSE-2.19](#)
- [2.20](#) Top 15 drugs in combination..... [RSE-2.20](#)
- [2.21](#) Most frequent two-way drug combinations

DRUG ABUSE EPISODES BY DEMOGRAPHIC & EPISODE CHARACTERISTICS

This group of tables presents cross-tabulations of estimates of patient demographic and ED episode characteristics for the total coterminous U.S. and for the 21 metropolitan areas oversampled in DAWN. No statistical tests are shown.

Drug Abuse Episodes, Total U.S.

- [2.01](#) Demographics & facility location by gender [RSE-2.01](#)
- [2.02](#) Race/ethnicity & age by gender [RSE-2.02](#)
- [2.05](#) Demographic & episode characteristics by drug use motive [RSE-2.05](#)

Episode Characteristics by Demographics

These tables provide the percentage distribution of drug abuse episodes for selected episode characteristics (i.e., drug concomitance, drug use motive, reason for ED contact, patient disposition, and facility location) by gender, race/ethnicity, and age.

- [2.03](#) By gender & race/ethnicity: All patients..... [RSE-2.03](#)
- [2.03a](#) By gender & race/ethnicity: Patients age 6-17 [RSE-2.03a](#)
- [2.03b](#) By gender & race/ethnicity: Patients age 18-34 [RSE-2.03b](#)

Data Table**RSE Table**

2.03c	By gender & race/ethnicity: Patients age 35 & older	RSE-2.03c
2.04	By age: All patients	RSE-2.04
2.04a	By age: White males	RSE-2.04a
2.04b	By age: White females	RSE-2.04b
2.04c	By age: Black males	RSE-2.04c
2.04d	By age: Black females	RSE-2.04d
2.04e	By age: Hispanic males	RSE-2.04e
2.04f	By age: Hispanic females	RSE-2.04f

DEMOGRAPHIC & EPISODE CHARACTERISTICS BY SELECTED DRUG GROUPS

This group of tables presents cross-tabulations of estimates of ED episodes and mentions for selected drugs by demographic and episode characteristics for the total coterminous U.S. and for the 21 metropolitan areas oversampled in DAWN. No statistical tests are shown.

Tables 2.07 through 2.10 show data tallied across all listed drug groups *within* the demographic category of interest. For example, the number and percent of mentions for selected drugs are tallied separately for each age group (Table 2.09). In contrast, Tables 2.11 through 2.18 show data tallied separately for each drug *across* the demographic categories of interest. For example, the percent distribution of mentions for each listed drug is tallied across age groups (Table 2.12).

Demographics, Total U.S.

2.07	Within gender	RSE-2.07
2.08	Within race/ethnicity	RSE-2.08
2.09	Within age	RSE-2.09
2.11	Across gender & race/ethnicity	RSE-2.11
2.12	Across age	RSE-2.12

Episode Characteristics, Total U.S.

2.14	Across reasons for ED contact	RSE-2.14
2.18	Across patient dispositions	RSE-2.18

Data Table**RSE Table****Drug Use Characteristics, Total U.S.**

2.10	Within drug use motive	RSE-2.10
2.13	Across drug use motives	RSE-2.13
2.15	Across sources of substance	RSE-2.15
2.16	Across forms of substance	RSE-2.16
2.17	Across routes of administration	RSE-2.17

Demographics, Total U.S. & 21 Metropolitan Areas

Tables 3.01 through 3.22 present estimates of total ED episodes and mentions of specific drugs by age, race/ethnicity, and gender for the total coterminous U.S. and the 21 DAWN metropolitan areas.

3.01	Total coterminous U.S.	RSE-3.01
3.02	Atlanta	RSE-3.02
3.03	Baltimore	RSE-3.03
3.04	Boston	RSE-3.04
3.05	Buffalo	RSE-3.05
3.06	Chicago	RSE-3.06
3.07	Dallas	RSE-3.07
3.08	Denver	RSE-3.08
3.09	Detroit.....	RSE-3.09
3.10	Los Angeles-Long Beach.....	RSE-3.10
3.11	Miami-Hialeah.....	RSE-3.11
3.12	Minneapolis-St. Paul.....	RSE-3.12
3.13	New Orleans.....	RSE-3.13
3.14	New York.....	RSE-3.14
3.15	Newark	RSE-3.15
3.16	Philadelphia.....	RSE-3.16
3.17	Phoenix	RSE-3.17
3.18	St. Louis	RSE-3.18
3.19	San Diego.....	RSE-3.19
3.20	San Francisco.....	RSE-3.20
3.21	Seattle	RSE-3.21
3.22	Washington, DC	RSE-3.22

Facility Location, 21 Metropolitan Areas

Table 3.23 presents estimates of total ED episodes and mentions of specific drugs by location inside or outside the central cities of the metropolitan areas represented in DAWN.

3.23	Episodes and mentions by central city/outside central city.....	RSE-3.23
------	---	----------

Data Table

RSE Table

POPULATION-BASED RATES FOR TOTAL U.S. & 21 METROPOLITAN AREAS

Table 3.24 presents the rate of ED drug abuse episodes and mentions of common illicit drugs per 100,000 population by metropolitan area, gender, and age. The table also shows the total population on which the rates were based. This table was previously located in Appendix I where it was numbered I-1. No statistical tests are shown.

3.24	Total coterminous U.S.	RSE-3.24
	Atlanta	
	Baltimore	
	Boston	
	Buffalo	
	Chicago	
	Dallas	
	Denver	
	Detroit	
	Los Angeles-Long Beach	
	Miami-Hialeah	
	Minneapolis-St. Paul	
	New Orleans	
	New York	
	Newark	
	Philadelphia	
	Phoenix	
	St. Louis	
	San Diego	
	San Francisco	
	Seattle	
	Washington, DC	
	National Panel	

4-YEAR TRENDS

Tables in this group present estimated numbers of ED drug abuse episodes and drug mentions for the most recent 4 years of DAWN ED data. One column in each table shows the results of statistical tests comparing the difference in estimates from this year to the year before. The significance levels are shown for differences that were statistically significant at less than the 0.05 level. Differences that are not statistically significant are denoted "N.S."

Drug Abuse Episodes, Total U.S.

4.01	By demographics	RSE-4.01
4.02	By episode characteristics	RSE-4.02
4.03	By selected drug groups	RSE-4.03
4.04	By metropolitan area.....	RSE-4.04

Data Table**RSE Table****Mentions of Common Illicit Drugs, Total U.S. & 21 Metropolitan Areas**

4.05a	Cocaine	RSE-4.05a
4.05b	Heroin/morphine	RSE-4.05b
4.05c	Marijuana/hashish	RSE-4.05c

Demographics & Selected Drug Groups by Metropolitan Area

The following tables present 4-year trends in the distribution of drug abuse episodes by patient demographic characteristics and of selected drug group mentions for the 21 DAWN metropolitan areas.

4.06a	Atlanta	RSE-4.06a
4.06b	Baltimore	RSE-4.06b
4.06c	Boston	RSE-4.06c
4.06d	Buffalo	RSE-4.06d
4.06e	Chicago	RSE-4.06e
4.06f	Dallas	RSE-4.06f
4.06g	Denver	RSE-4.06g
4.06h	Detroit.....	RSE-4.06h
4.06i	Los Angeles-Long Beach.....	RSE-4.06i
4.06j	Miami-Hialeah.....	RSE-4.06j
4.06k	Minneapolis-St. Paul.....	RSE-4.06k
4.06l	New Orleans.....	RSE-4.06l
4.06m	New York.....	RSE-4.06m
4.06n	Newark	RSE-4.06n
4.06o	Philadelphia	RSE-4.06o
4.06p	Phoenix	RSE-4.06p
4.06q	St. Louis	RSE-4.06q
4.06r	San Diego.....	RSE-4.06r
4.06s	San Francisco.....	RSE-4.06s
4.06t	Seattle	RSE-4.06t
4.06u	Washington, DC	RSE-4.06u